参麦注射液联合替格瑞洛治疗冠心病心绞痛的临床研究

目的 探讨参麦注射液联合替格瑞洛片治疗冠心病心绞痛的临床疗效。方法 选取2020年7月—2022年3月在海安市人民医院就诊的112例冠心病心绞痛患者，根据随机数字表法将所有患者分为对照组和治疗组，每组各56例。对照组患者口服替格瑞洛片，90 mg/次，2次/d。治疗组在对照组基础上静脉滴注参麦注射液，100 mL加入250 mL葡萄糖溶液中，1次/d。两组患者连续治疗14 d。观察两组的临床疗效，比较两组的心绞痛症状以及血清中妊娠相关血浆蛋白A（PAPP-A）、高迁移率族蛋白B1（HMGB1）、肌红蛋白（Mb）水平。结果 治疗后，治疗组的总有效率为96.43%，明显高于对照组的总有效率83.93%，组间差异有统计学意义（P＜0.05）。治疗后，两组的发作频率、最长持续时间、数字疼痛强度量表（NRS）评分均明显降低（P＜0.05），且治疗组发作频率、最长持续时间、NRS评分明显低于对照组，差异有统计学意义（P＜0.05）。治疗后，两组的血清PAPP-A、HMGB1、Mb水平明显降低（P＜0.05）；治疗后，治疗组的血清PAPP-A、HMGB1、Mb水平低于对照组（P＜0.05）。结论 参麦注射液联合替格瑞洛片可提高冠心病心绞痛的疗效，减轻心绞痛症状，降低心肌损伤，并且具有良好安全性。

Clinical study on Shenmai Injection combined with ticagrelor in treatment of angina pectoris of coronary heart disease

Objective To investigate the clinical effect of Shenmai Injection combined with Ticagrelor Tablets in treatment of angina pectoris of coronary heart disease.Methods Patients (84 cases) with angina pectoris of coronary heart disease in Hai''an People''s Hospital from July 2020 to March 2022 were divided into control and treatment groups according to the random number table method,and each group had 56 cases.Patients in the control group were po administered with Ticagrelor Tablets,90 mg/time,twice daily.Patients in the treatment group were po administered with Shenmai Injection on the basis of the control group,100 mL added into glucose solution 250 mL,once daily.Patients in two groups were treated for 14 d.After treatment,the clinical efficacies were evaluated,and the angina pectoris symptoms and the serum levels of PAPP-A,HMGB1,and Mb in two groups were compared.Results After treatment,the total effective rate of the treatment group was 96.43%,which was significantly higher than 83.93% of the control group,and the difference was statistically significant between the groups (P the curative effect of angina pectoris of coronary heart disease,further reduce the symptoms of angina pectoris,reduce myocardial injury,with good safety.<0.05).After treatment,the attack frequency,longest duration of angina pectoris,and the NRS score of two groups were significantly decreased (P <0.05),and the attack frequency and longest duration of angina pectoris,and the NRS score of the treatment group were significantly lower than those of the control group,and the difference was statistically significant between the groups (P<0.05).After treatment,the serum levels of PAPP-A,HMGB1,and Mb in two groups were significantly decreased (P<0.05).After treatment,the serum levels of PAPP-A,HMGB1,and Mb in the treatment group were lower than those in the control group (P<0.05).Conclusion Shenmai Injection combined with Ticagrelor Tablets can improve